Epoetin Alfa

• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending
  2025-523544-12-00 Phase III 14 countries Takeda Development Center Americas Inc.
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea… Recruiting
  2022-501980-42-00 Phase III 20 countries Astellas Pharma Global Development Inc.
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 Phase III 6 countries Novartis Pharma AG
• A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting
  2024-515354-24-00 Phase I/II 2 countries Groupe Francophone Des Myelodysplasies
• EPO-TRAUMA Recruiting
  2023-506081-31-00 Phase III 6 countries University College Dublin
• 1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended
  2022-500430-29-00 Phase III 8 countries Celgene Corp.
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended
  2022-501485-22-00 Phase III 14 countries Celgene Corp.
• A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI… Ended
  2024-515356-21-00 Phase III 1 country Groupe Francophone Des Myelodysplasies

Showing 1–8 of 8 trials